Navigation Links
Charles C. Harwood, Jr., Joins Cellectar, Inc.'s Board of Directors
Date:9/18/2008

MADISON, Wis., Sept. 18 /PRNewswire/ -- Cellectar, Inc., a privately-held radiopharmaceuticals company that designs and develops products to detect, treat and monitor human cancers, today announced the appointment of Charles C. Harwood, Jr., to the Company's Board of Directors.

Mr. Harwood, 55, is a Healthcare Industry Advisor for Avista Capital Partners, a NYC-based private equity firm. Prior to working with Avista, Mr. Harwood was President and Chief Executive Officer of privately-held Focus Diagnostics, Inc. from 2002 until the company's sale in 2006. With more than 20 years of experience in the healthcare industry, he has also served as Senior Vice President and Chief Financial Officer of Covance, Inc., one of world's largest drug development service companies.

"Charlie brings exceptional financial and transaction expertise to the Cellectar Board," commented William Clarke, MD, M.Sc, President and CEO of Cellectar. "His years of experience in the drug development industry will prove beneficial to the Company as we advance our radiopharmaceutical products toward clinical testing and commercialization."

Mr. Harwood also serves on the Board of Directors at BioReliance, Inc., a contract research organization specializing in biological safety testing and specialized toxicology, RadPharm, Inc., a privately-held contract research organization located in Princeton, NJ, and Itero Biopharmaceuticals, Inc., a development stage company located in the San Francisco Bay Area.

About Cellectar

Cellectar, Inc. is a radiopharmaceutical company that designs, develops and manufactures products to detect, treat and monitor a wide variety of human cancers. Cellectar's novel product candidates combine lipid-like molecules, phospholipid ethers (PLEs) analogs, with radioisotopes that can either image or destroy malignant cells. Cellectar's products' unique mechanism of action is based on their accumulation and selective retention in malignant tumors and not in normal cells. The Company's operations are based in Madison, WI. Cellectar has previously raised approximately $22.0 million from angel and venture capital investors; including Continuum Investment Partners and Venture Investors, LLC. For further information about Cellectar, visit the Company's website at http://www.cellectar.com.


'/>"/>
SOURCE Cellectar, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ocular Biopharmaceutical Company Charlesson Announces $1.6MM in New Funding and Upcoming Presentations at The Association for Research in Vision and Ophthalmology
2. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
3. Dr. Charles A. Sims of California Cryobanks Family Cord Blood Services Named to National Stem Cell Advisory Council
4. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
5. Informed Medical Communications Appoints Charles T. Saldarini to Board of Directors
6. Industry Pioneer Joins Profectus BioSciences to Support Innovation in Therapeutic and Preventative Vaccines
7. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
8. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
9. The National Cancer Institute Joins the Global Community of Scientists Now Using BIOMARKERcenter From Thomson Reuters
10. GM Exec Joins Bio-Reaction Industries Board of Directors
11. Nicholas J. Hart Joins Emisphere as Vice President, Strategy and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... -- Andrew D Zelenetz , ... Published recently in Oncology & ... Andrew D Zelenetz , discusses the fact ... placing an increasing burden on healthcare systems worldwide, ... the patents on many biologics expiring, interest in ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... line of intelligent tools designed, tuned and optimized exclusively for Okuma CNC machining ... Chicago. The result of a collaboration among several companies with expertise in toolholding, ...
Breaking Biology Technology:
(Date:4/28/2016)... SAN FRANCISCO and BANGALORE, India ... part of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... service provider, today announced a global partnership that ... convenient way to use mobile banking and payment services. ... Mobility is a key innovation area for financial services, but ...
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
Breaking Biology News(10 mins):